Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer. Prognostic ...
Artificial intelligence An MMAI model can accurately predict long-term outcomes in patients with high-risk prostate cancer, a study suggests. A multi-modal artificial intelligence (MMAI) model can ...
2d
Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today ...
CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of ...
The new MMAI risk grouping system can potentially reduce overtreatment and undertreatment of localized prostate cancer. Deep learning multimodal artificial intelligence (MMAI) models outperformed ...
The MarketWatch News Department was not involved in the creation of this content. Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will ...
Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project) ...
On August 8, 2014, the Illinois Department of Healthcare and Family Services (HFS) issued a three-page memo to long term care nursing home providers clarifying several issues regarding participation ...
MMAI leads blockchain innovation, delivering unique crypto wallet, developing immersive metaverse, and launching its own blockchain. ORANGE, CA, UNITED STATES, June ...
Insilico Medicine announced the expansion of its MMAI Gym, a foundation-model training framework and platform for large-scale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results